CUREosity GmbH, the innovative MedTech company from Düsseldorf, announces the successful conclusion of a growth financing round. A total of 3.8 million euros was committed by existing and new investors in the completed growth financing round. Caesar van Heyningen (CEO): "The current successful course - consisting of scaling markets and high-quality updates of our therapy software - is strengthened by this financing. We plan to invest heavily in commercial expansion, incorporating tomorrow's technological possibilities into our product roadmap today. With this financing round, we can ensure financial independence and sustainable business operations. A privilege - especially in tight market conditions."
CUREosity Management: Caesar van Heyningen (CEO), Thomas Saur (CVO), and Stefan Arand (CTO)
With the signing and notarization, it has been official since June 21, 2024: With 3.8 million euros in equity, CUREOSITY can continue to grow sustainably in the future. The dedicated team has already come a long way with CUREOSITY: Since the market launch of the virtual reality therapy (VR therapy) CUREO®, the software-as-a-service company has grown strongly and is now in use in almost 200 therapeutic facilities. The additional capital will be used, among other things, to further expand CUREO®'s market leadership in the field of VR therapy.
Among others, the existing investor TechVision Fonds (TVF) and the Belgian family office Nomainvest have contributed as new co-investors. The venture capital fund TVF, based in Aachen, specializes in companies in the medical technology sector, among others, and has been supporting CUREOSITY since 2021. Björn Lang, Partner at TVF: "CUREOSITY solves the problem of the shortage of skilled workers in the field of therapy. Especially due to demographic change, smart solutions like CUREO® VR therapy are highly relevant to society. We look forward to participating in the solutions and successes in the future."
The growth financing round was accompanied by the law firms ADVANT Beiten and Forvis Mazars, whom CUREOSITY would like to thank for their productive and successful collaboration.
Comentarios